Michael Donoviel

Michael Donoviel is a highly experienced professional in the field of medicine and biochemistry, currently serving as a Senior Medical Science Liaison at Alpine Immune Sciences, Inc. since May 2024. Prior to this role, Donoviel held the position of Medical Director for Dermatology & Rare Diseases at Priovant Therapeutics from August 2022 to April 2024, and previously worked as a Medical Science Liaison III at Arena Pharmaceuticals until its acquisition by Pfizer in March 2022. Donoviel has extensive experience in medical science liaison roles at Mallinckrodt Pharmaceuticals and IKARIA, Inc., as well as leadership as a Principal Scientist in Immunology at Lexicon Pharmaceuticals. Academic qualifications include a Ph.D. in Biochemistry and Molecular Biology from the University of Washington and a Bachelor's Degree in Biochemistry and Cell Biology from UC San Diego. Donoviel's early research experience includes significant roles at the University of Toronto and the University of California San Diego, contributing to various scientific advancements.